-
1 Comment
Nyxoah S.A is currently in a long term uptrend where the price is trading 30.6% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Nyxoah S.A gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Medical Instruments & Supplies |
| Exchange | BR |
| CurrencyCode | EUR |
| ISIN | BE0974358906 |
| PE Ratio | None |
|---|---|
| Target Price | 9 |
| Beta | 0.89 |
| Market Cap | 67M |
| Dividend Yield | None |
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NYXH.BR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026